A BREAKTHROUGH IN TRICUSPID VALVE REPAIR
Mitralign has developed an approach to treating tricuspid valve regurgitation, or tricuspid valve insufficiency, using the company's direct annuloplasty platform with an innovative delivery system designed for direct transcatheter tricuspid valve repair.
The valve between the right atrium and the right ventricle is called the tricuspid valve and it opens to allow blood to be pumped from the right atrium in to the right ventricle. Once the blood has passed through the valve closes so the blood cannot pass back. Tricuspid regurgitation (TR) occurs when the tricuspid valve fails to open and close properly, causing blood to flow backward into the right atrium. If left untreated, TR can lead to heart enlargement and heart failure. In the U.S. alone, there are an estimated 1.6 million patients suffering from TR1. It is estimated that 50% of patients with mitral regurgitation have moderate to severe tricuspid regurgitation2. TR is currently undertreated by surgery. In the U.S. surgeons treat only 5,500 patients per year, most of them in conjunction with left heart surgeries3. When treated, surgeons choose to repair 90% of the time over replacement (10%)3.
The March 2015 issue of the Journal of the American College of Cardiology (JACC) offers a detailed reporting of one of the first compassionate use procedures utilizing direct transcatheter tricuspid valve repair (TTVR) for severe TR. The patient was treated by Prof. Dr. med. J. Schofer of the Medicare Center and Department for Percutaneous Interventions of Structural Heart Disease, Albertinen Heart Center, Hamburg, Germany using the Mitralign® Percutaneous Annuloplasty System for the treatment of tricuspid regurgitation. In an accompanying editorial, William W. O’Neill, MD, and Brian P. O’Neill, MD commented that tricuspid regurgitation “remains an undertreated problem” noting mortality rates for patients undergoing surgery.